Biohaven Shares Rise After FDA Accepts Vyglxia Resubmission for Review

MT newswire2026/10/22 19:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:30 PM EDT, 10/22/2026 (MT Newswires) -- Biohaven (BHVN) shares were up roughly 26% in Thursday trading after the company said the US Food and Drug Administration has accepted its resubmitted new drug application for Vyglxia (troriluzole) for review in spinocerebellar ataxia. The FDA considers the resubmission a complete response to its Nov. 4, 2025 action letter and set a target decision date in Q1 2027, the company said. The agency plans an advisory committee meeting to gather outside input and will announce the date later, it added. Price: 14.80, Change: +3.05, Percent Change: +25.91

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.

华尔街见闻•2026/11/06 23:26